ADVERTISEMENT
search.svg

COVID-19 Therapeutics

Students

Featured Updates

Nirmatrelvir and Ritonavir (Paxlovid™): An Oral Antiviral for the Treatment of COVID-19

CPE webinar that reviews the clinical use of Paxlovid and discusses available efficacy and safety data.

Molnupiravir: An Oral Antiviral for the Treatment of COVID-19

CPE webinar that reviews the clinical use of molnupiravir and discusses available efficacy and safety data.

Monoclonal Antibodies: Assessment and Administration of COVID-19 Therapy

Free training program designed to fully satisfy the requirements of the PREP Act by supplementing the Pharmacy-based Immunization Delivery certificate training programs.

General Information

HHS COVID-19 Therapeutics Locator is a national map healthcare providers can use to direct patients to COVID-19 therapies.

COVID-19 Therapeutics: Evidence-based Care and Practice Opportunities (October 14, 2021)
This webinar looks at the controversy around ivermectin and reviews how studies inform evidence-based decision making. Then hear how pharmacists can provide COVID-19 therapeutics to their community. (APhA Open Forum Webinar - Video - Slides)

Authority to Provide COVID-19 Therapeutics (September 17, 2021)
FAQ on the authority to order and/or administer COVID-19 therapeutics and the requirements that must be met. (Know the Facts – PDF)

ASPR’s Authority to Provide COVID-19 Therapeutics Fact Sheet outlines the authority for pharmacists and pharmacy technicians and interns to provide certain COVID-19 therapeutics during the public health emergency, subject to certain requirements. (September 8, 2021)

The Long-term Effects of COVID-19 Disease: Impact on Patient Care (May 13, 2021)
The long-term effects of COVID-19 are not well understood, but it is important that pharmacists are aware of how these symptoms may present in their patients. This webinar discusses the long-term effects of COVID-19 and the advantages of COVID-19 vaccination. (APhA Open Forum Webinar - Video - Slides)

15 on COVID-19 Video Series
Learn about COVID-19 therapeutics with APhA’s short video series designed to help you separate fact from fiction and rumor from hypothesis. Get the answers you need to educate yourself, your colleagues, and your patients about COVID-19.

Oral Antivirals

Molnupiravir

Molnupiravir: An Oral Antiviral for the Treatment of COVID-19 (January 5, 2022)
Molnupiravir is an oral antiviral authorized to be administered in the outpatient setting for individuals with laboratory-confirmed COVID-19 who exhibit mild to moderate symptoms. We will review the indications, discuss available efficacy and safety data, and consider the clinical use of molnupiravir. (Education During COVID-19 – CPE)

Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Paxlovid

Nirmatrelvir and Ritonavir (Paxlovid™): An Oral Antiviral for the Treatment of COVID-19 (January 7, 2022)
Paxlovid is the first oral antiviral authorized to be administered in the outpatient setting for individuals with laboratory-confirmed COVID-19 who exhibit mild to moderate symptoms. We will review the indications, discuss currently available efficacy and safety data, and consider its place in therapy. (Education During COVID-19 – CPE)

ISMP Medication Safety Issues with Paxlovid (January 3, 2022)

Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

Monoclonal Antibody Therapies

Remdesivir

  • Remdesivir RCT Data (June 5, 2020)
    FDA issued an emergency use authorization allowing the prescription of remdesivir for the treatment of COVID-19 on May 1, 2020. On this episode of 15 on COVID-19, we take a closer look at the trial details and the resulting data. (APhA 15 on COVID-19 Video)
  • Remdesivir Updates (May 4, 2020)
    Remdesivir is back in the news. On this episode of 15 on COVID-19 episode, we examine the results of two randomized, placebo-controlled trials looking at remdesivir for the treatment of COVID-19. (APhA 15 on COVID-19 Video)
  • Viral Properties and Remdesivir Updates (April 24, 2020)
    New information and new rumors about COVID-19 come out every day. Watch this episode of 15 on COVID-19, where we’ll dispel remdesivir rumors and revisit some of the physical properties of the COVID-19 virus, such as aerosolization properties and surface stability. (APhA 15 on COVID-19 Video)
  • Remdesivir (April 3, 2020)
    Have you heard about remdesivir’s potential as a treatment for COVID-19? On this episode of 15 on COVID-19, we explore the possibilities. (APhA 15 on COVID-19 Video)

Additional Therapeutics

  • NIH’s COVID-19 Therapeutics Prioritized for Testing in Clinical Trials lists medications being studied, but not yet recommended to prevent or treat COVID-19 disease.
  • Anticoagulation (May 15, 2020)
    Have you heard that patients with COVID-19 are at increased risk of clots? In this 15 on COVID-19 episode, we examine the available evidence and review the literature on the benefits of anticoagulation in patients with COVID-19. (APhA 15 on COVID-19 Video)
  • Dexamethasone (July 31, 2020)
    Finally, a drug has demonstrated improved survival outcomes in COVID-19. Fortunately for everyone, that drug is a widely available, inexpensive drug that we are all familiar with: dexamethasone. Watch this episode of 15 on COVID-19 for a review of the dexamethasone data in COVID-19. (APhA 15 on COVID-19 Video)
  • IL-6 Antagonists (April 6, 2020)
    Tocilizumab, usually used to treat autoimmune disorders, has begun appearing in conversations about COVID-19. Why would an antirheumatic drug be useful for COVID-19? This episode of 15 on COVID-19 outlines the connection. (APhA 15 on COVID-19 Video)

Guidelines